These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 8091742)

  • 61. Resistance of vaccinia virus to inactivation by solvent/detergent treatment of blood products.
    Roberts P
    Biologicals; 2000 Mar; 28(1):29-32. PubMed ID: 10799053
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Investigation of an outbreak of hepatitis A in Irish haemophilia A patients.
    Lawlor E; Johnson Z; Thornton L; Temperley I
    Vox Sang; 1994; 67 Suppl 1():18-9; discussion 20. PubMed ID: 8091729
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Viral safety of a new highly purified factor VIII (OCTATE).
    Biesert L; Lemon S; Goudeau A; Suhartono H; Wang L; Brede HD
    J Med Virol; 1996 Apr; 48(4):360-6. PubMed ID: 8699169
    [TBL] [Abstract][Full Text] [Related]  

  • 64. [Vaccination against hepatitis A].
    Balli F; Di Biase AR; Viola L
    Pediatr Med Chir; 1996; 18(3):259-62. PubMed ID: 8966125
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Products for the treatment of hemophilia A and B prepared by ion exchange chromatography.
    Sultan Y; Boyeldieu D; Stieltjes N
    Nouv Rev Fr Hematol (1978); 1994; 36 Suppl 1():S59-60. PubMed ID: 8177717
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Removal of small nonenveloped viruses by antibody-enhanced nanofiltration during the manufacture of plasma derivatives.
    Kreil TR; Wieser A; Berting A; Spruth M; Medek C; Pölsler G; Gaida T; Hämmerle T; Teschner W; Schwarz HP; Barrett PN
    Transfusion; 2006 Jul; 46(7):1143-51. PubMed ID: 16836561
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Hepatitis A transmission by factor IX concentrates.
    Lawlor E; Graham S; Davidson E; Yap PL; Cunningham C; Daly H; Temperley IJ
    Vox Sang; 1996; 71(2):126-8. PubMed ID: 8873425
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Real time quantitative PCR as a method to evaluate xenotropic murine leukemia virus removal during pharmaceutical protein purification.
    Shi L; Chen Q; Norling LA; Lau AS; Krejci S; Xu Y
    Biotechnol Bioeng; 2004 Sep; 87(7):884-96. PubMed ID: 15334415
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Von Willebrand factor multimers in virus-inactivated plasmas and F VIII concentrates.
    Budde U; Drewke E
    Beitr Infusionsther Transfusionsmed; 1994; 32():408-14. PubMed ID: 9422121
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Parvovirus B19 DNA in Factor VIII concentrates: effects of manufacturing procedures and B19 screening by nucleic acid testing.
    Geng Y; Wu CG; Bhattacharyya SP; Tan D; Guo ZP; Yu MY
    Transfusion; 2007 May; 47(5):883-9. PubMed ID: 17465954
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Virus-binding activity of fibronectin: masking of hepatitis A virus.
    Seelig R; Pott G; Seelig HP; Liehr H; Metzger P; Waldherr R
    J Virol Methods; 1984 Jul; 8(4):335-47. PubMed ID: 6088567
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Infection of hepatitis A virus in Japanese haemophiliacs.
    Hayashi K; Fukuda Y; Nakano I; Katano Y; Nagano K; Yokozaki S; Hayakawa T; Toyoda H; Takamatsu J
    J Infect; 2001 Jan; 42(1):57-60. PubMed ID: 11243755
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Viral inactivation vs biological activity.
    Barrowcliffe TW
    Dev Biol Stand; 1993; 81():125-35. PubMed ID: 8174795
    [TBL] [Abstract][Full Text] [Related]  

  • 74. A higher than expected incidence of factor VIII inhibitors in multitransfused haemophilia A patients treated with an intermediate purity pasteurized factor VIII concentrate.
    Peerlinck K; Arnout J; Gilles JG; Saint-Remy JM; Vermylen J
    Thromb Haemost; 1993 Feb; 69(2):115-8. PubMed ID: 8456422
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Inactivation kinetics of model and relevant blood-borne viruses by treatment with sodium hydroxide and heat.
    Borovec S; Broumis C; Adcock W; Fang R; Uren E
    Biologicals; 1998 Sep; 26(3):237-44. PubMed ID: 10208725
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Virus inactivation by solvent/detergent treatment using Triton X-100 in a high purity factor VIII.
    Roberts PL
    Biologicals; 2008 Sep; 36(5):330-5. PubMed ID: 18674928
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Hepatitis A virus and polymerase chain reaction amplification: methodology and results.
    Robertson BH; Normann A; Graff J; Flehmig B; Friedberg D; Shouval D
    Blood Coagul Fibrinolysis; 1995 Jul; 6 Suppl 2():S27-31. PubMed ID: 7495964
    [TBL] [Abstract][Full Text] [Related]  

  • 78. [Seroepidemiology of hepatitis A virus infection in medical and nursing students. The role of vaccination].
    Buti M; Campins M; Jardí R; Navas E; Cotrina M; Llobet E; Vaqué J; Esteban R
    Gastroenterol Hepatol; 1996 Apr; 19(4):199-202. PubMed ID: 8665357
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Affinity chromatography to remove viruses during preparation of plasma derivatives.
    Lawrence JE
    Dev Biol Stand; 1993; 81():191-7. PubMed ID: 8174803
    [TBL] [Abstract][Full Text] [Related]  

  • 80. A minipool process for solvent-detergent treatment of cryoprecipitate at blood centres using a disposable bag system.
    Burnouf T; Goubran HA; Radosevich M; Sayed MA; Gorgy G; El-Ekiaby M
    Vox Sang; 2006 Jul; 91(1):56-62. PubMed ID: 16756602
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.